Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea. The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.
Columbia University Medical Center
New York, New York, United States
RECRUITINGFree living energy expenditure
The investigators will measure energy expenditure using the doubly labeled water (DLW) technique and actigraphy.
Time frame: Data will be obtained in the last 2 weeks of each study phase (HGNS-on or HGNS-off)
Hypoxic burden
The investigators will measure hypoxic burden based on the home sleep testing obtained during the study.
Time frame: Data will be obtained in the last 2 weeks of each study phase (HGNS-on or HGNS-off).
Insulin resistance
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) will be derived from fasting glucose and insulin
Time frame: These measures will be taken at the end of each study phase (duration of 2-4 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.